announcement

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
30 May 2014

PRIMA BIOMED TO HOST CONFERENCE CALL TO DISCUSS ABSTRACT PRESENTED AT
ASCO ON NEW INTERIM OVERALL SURVIVAL AND FINAL PROGRESSION FREE SURVIVAL
DATA FOR THE COMPANY’S CAN-003 TRIAL


Webcast to Include Dr. Heidi Gray, Lead Investigator, and Dr. Brad Monk, Chair of Prima’s
Clinical Advisory Board.

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, “the Company”)
today advised that the Company will host a conference call and webcast covering Dr. Heidi Gray’s
oral presentation at the American Society of Clinical Oncology (“ASCO”) to be given on May 31,
2014 in Chicago, IL. The call and webcast will include discussions from both Dr. Gray and Dr. Monk
on data presented at ASCO.

As earlier announced, the final CAN-003 progression free survival data and interim overall
survival data was accepted for oral presentation by Dr. Heidi Gray at ASCO’s 2014 Annual
Meeting. ASCO abstract #5504 entitled “Progression-free survival in ovarian cancer patients
in second remission is improved with mucin 1-autologous dendritic cell therapy” is available
at http://abstracts.asco.org/.

Webcast and Conference Call Details:
The call is scheduled for Tuesday, June 3rd
at 11am (Sydney local time). This corresponds to
Monday, June 2
nd
at 9pm U.S. Eastern daylight time. The conference call dial-in numbers are
as follows:

Participant Numbers:

Australia Toll Free 1800 606 599
Australia Local +61 2 9007 8047
Canada/USA 1 855 237 2970
Germany 0800 189 9369

The call will also be audio webcast with additional supplemental slides available via
http://www.media-server.com/m/go/primabiomed-june-2014. Before launching the
webcast, it is recommended to click on the link and then on “test your system
configuration.” A replay of the webcast will be available through Prima’s website following
the live event.



About the CAN-003 Clinical Trial
CAN-003 is a 63-patient phase 2 study evaluating the effects of CVac, as compared to an
observational standard of care arm (OSC), in epithelial ovarian cancer patients in complete
remission after first or second line treatment. In accordance with the protocol design, the
first seven patients on the trial were all assigned to receive CVac in order to test the
comparability of product manufacturing in a new facility.

The subsequent 56 patients were randomized 1:1 to either the CVac group or observational
standard of care (OSC) and included in the intent-to-treat analysis. 36 patients were in first
remission (19 patients were assigned to CVac and 17 to OSC) and 20 patients were in second
remission (10 patients were each assigned to CVac or OSC). Final PFS data was analysed after
thorough quality control reviews of investigator-evaluated progression and appropriate
censoring of data from patients who had not progressed during the study.

The primary objectives of the trial are to determine the safety of CVac administration and to
determine CVac’s effect on progression-free survival. Secondary objectives of the trial are to
determine CVac’s effect of overall survival and to evaluate host immunologic responses to
Cvac.

About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular
therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its
technology and expertise to bring innovative treatment options to market for patients and to
maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-
based product currently in clinical trials. www.primabiomed.com.au

For further information please contact:

USA Investor/Media:
Adam Holdsworth, ProActive Capital
+1 (646) 862 4607; [email protected]

Australia Investor/Media:
Mr Matthew Gregorowski, Citadel Communications
+61 (0) 422 534 755; [email protected]

Europe Investor/Media:
Mr. Axel Mühlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlha